HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
Human papillomavirus (HPV) L1 VLP-based vaccines are protective against HPV vaccine-related types; however, the correlates of protection have not been defined. We observed that vaccination with Cervarix™ induced cross-neutralizing antibodies for HPV types for which evidence of vaccine efficacy has been demonstrated (HPV31/45) but not for other types (HPV52/58). In addition, HPV31/45 cross-neutralizing titers showed a significant increase with number of doses (HPV31, p<0.001; HPV45, p<0.001) and correlated with HPV16/18 neutralizing titers, respectively. These findings raise the possibility that cross-neutralizing antibodies are effectors of cross-protection observed for the HPV16/18 vaccine.
HPV Immunology Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD 21702, USA.
Troy J
TJ
Kemp
Allan
A
Hildesheim
Mahboobeh
M
Safaeian
Joseph G
JG
Dauner
Yuanji
Y
Pan
Carolina
C
Porras
John T
JT
Schiller
Douglas R
DR
Lowy
Rolando
R
Herrero
Ligia A
LA
Pinto
D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D000917:Antibody Formation; D056738:Cross Protection; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology*
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18
Lancet. 2009 Jul 25;374(9686):301-14
19586656
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11553-7
8524802
J Infect Dis. 2009 Apr 1;199(7):926-35
19236279
Vaccine. 2008 Sep 2;26(37):4795-808
18640170
J Virol. 1995 Jun;69(6):3959-63
7745754
Lancet. 2004 Nov 13-19;364(9447):1757-65
15541448
Virology. 2006 Sep 30;353(2):451-62
16863657
Br J Cancer. 2006 Dec 4;95(11):1459-66
17117182
Gynecol Oncol. 2009 Dec;115(3 Suppl):S1-6
19217149
Hum Vaccin. 2007 Jul-Aug;3(4):109-15
17611417
Vaccine. 2008 Jul 4;26(29-30):3608-16
18541349
JAMA. 2007 Aug 15;298(7):743-53
17699008
Lancet Oncol. 2005 May;6(5):271-8
15863374